Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor

Summary: Atypical teratoid/rhabdoid tumor (AT/RT), which harbors SMARCB1 mutation and exhibits a characteristic histology of rhabdoid cells, has a poor prognosis because of the lack of effective treatments. Here, we establish human SMARCB1-deficient pluripotent stem cells (hPSCs). SMARCB1-deficient...

Full description

Bibliographic Details
Main Authors: Yukinori Terada, Norihide Jo, Yoshiki Arakawa, Megumi Sakakura, Yosuke Yamada, Tomoyo Ukai, Mio Kabata, Kanae Mitsunaga, Yohei Mineharu, Sho Ohta, Masato Nakagawa, Susumu Miyamoto, Takuya Yamamoto, Yasuhiro Yamada
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124719301718
id doaj-a21290f37a8448f6882ad39ced9eab91
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Yukinori Terada
Norihide Jo
Yoshiki Arakawa
Megumi Sakakura
Yosuke Yamada
Tomoyo Ukai
Mio Kabata
Kanae Mitsunaga
Yohei Mineharu
Sho Ohta
Masato Nakagawa
Susumu Miyamoto
Takuya Yamamoto
Yasuhiro Yamada
spellingShingle Yukinori Terada
Norihide Jo
Yoshiki Arakawa
Megumi Sakakura
Yosuke Yamada
Tomoyo Ukai
Mio Kabata
Kanae Mitsunaga
Yohei Mineharu
Sho Ohta
Masato Nakagawa
Susumu Miyamoto
Takuya Yamamoto
Yasuhiro Yamada
Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor
Cell Reports
author_facet Yukinori Terada
Norihide Jo
Yoshiki Arakawa
Megumi Sakakura
Yosuke Yamada
Tomoyo Ukai
Mio Kabata
Kanae Mitsunaga
Yohei Mineharu
Sho Ohta
Masato Nakagawa
Susumu Miyamoto
Takuya Yamamoto
Yasuhiro Yamada
author_sort Yukinori Terada
title Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor
title_short Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor
title_full Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor
title_fullStr Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor
title_full_unstemmed Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor
title_sort human pluripotent stem cell-derived tumor model uncovers the embryonic stem cell signature as a key driver in atypical teratoid/rhabdoid tumor
publisher Elsevier
series Cell Reports
issn 2211-1247
publishDate 2019-03-01
description Summary: Atypical teratoid/rhabdoid tumor (AT/RT), which harbors SMARCB1 mutation and exhibits a characteristic histology of rhabdoid cells, has a poor prognosis because of the lack of effective treatments. Here, we establish human SMARCB1-deficient pluripotent stem cells (hPSCs). SMARCB1-deficient hPSC-derived neural progenitor-like cells (NPLCs) efficiently give rise to brain tumors when transplanted into the mouse brain. Notably, activation of an embryonic stem cell (ESC)-like signature confers a rhabdoid histology in SMARCB1-deficient NPLC-derived tumors and causes a poor prognosis. Consistently, we find the activation of the ESC-like gene expression signature and an ESC-like DNA methylation landscape in clinical specimens of AT/RT. Finally, we identify candidate genes that maintain the activation of the ESC-like signature and the growth of AT/RT cells. Collectively, SMARCB1-deficient hPSCs offer the human models for AT/RT, which uncover the role of the activated ESC-like signature in the poor prognosis and unique histology of AT/RT. : Terada et al. present SMARCB1-deficient human pluripotent stem cell-derived atypical teratoid/rhabdoid tumor (AT/RT) models and show that ESC-like signature is a critical driver of malignant phenotypes of AT/RT. Genetic ablation targeting the maintenance of pluripotency inhibits AT/RT cell growth, suggesting that the ESC-like signature could be a promising therapeutic target for AT/RT. Keywords: atypical teratoid/rhabdoid tumor, pediatric tumor, embryonic stem cell, induced pluripotent stem cell, ESC-like signature, pluripotency, dedifferentiation, SMARCB1
url http://www.sciencedirect.com/science/article/pii/S2211124719301718
work_keys_str_mv AT yukinoriterada humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT norihidejo humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT yoshikiarakawa humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT megumisakakura humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT yosukeyamada humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT tomoyoukai humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT miokabata humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT kanaemitsunaga humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT yoheimineharu humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT shoohta humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT masatonakagawa humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT susumumiyamoto humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT takuyayamamoto humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
AT yasuhiroyamada humanpluripotentstemcellderivedtumormodeluncoverstheembryonicstemcellsignatureasakeydriverinatypicalteratoidrhabdoidtumor
_version_ 1725088824365678592
spelling doaj-a21290f37a8448f6882ad39ced9eab912020-11-25T01:30:56ZengElsevierCell Reports2211-12472019-03-01261026082621.e6Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid TumorYukinori Terada0Norihide Jo1Yoshiki Arakawa2Megumi Sakakura3Yosuke Yamada4Tomoyo Ukai5Mio Kabata6Kanae Mitsunaga7Yohei Mineharu8Sho Ohta9Masato Nakagawa10Susumu Miyamoto11Takuya Yamamoto12Yasuhiro Yamada13Division of Stem Cell Pathology, Center for Experimental Medicine and Systems Biology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan; Department of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDivision of Stem Cell Pathology, Center for Experimental Medicine and Systems Biology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDivision of Stem Cell Pathology, Center for Experimental Medicine and Systems Biology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDivision of Stem Cell Pathology, Center for Experimental Medicine and Systems Biology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, JapanDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan; AMED-CREST, AMED 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, JapanDivision of Stem Cell Pathology, Center for Experimental Medicine and Systems Biology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan; AMED-CREST, AMED 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan; Corresponding authorSummary: Atypical teratoid/rhabdoid tumor (AT/RT), which harbors SMARCB1 mutation and exhibits a characteristic histology of rhabdoid cells, has a poor prognosis because of the lack of effective treatments. Here, we establish human SMARCB1-deficient pluripotent stem cells (hPSCs). SMARCB1-deficient hPSC-derived neural progenitor-like cells (NPLCs) efficiently give rise to brain tumors when transplanted into the mouse brain. Notably, activation of an embryonic stem cell (ESC)-like signature confers a rhabdoid histology in SMARCB1-deficient NPLC-derived tumors and causes a poor prognosis. Consistently, we find the activation of the ESC-like gene expression signature and an ESC-like DNA methylation landscape in clinical specimens of AT/RT. Finally, we identify candidate genes that maintain the activation of the ESC-like signature and the growth of AT/RT cells. Collectively, SMARCB1-deficient hPSCs offer the human models for AT/RT, which uncover the role of the activated ESC-like signature in the poor prognosis and unique histology of AT/RT. : Terada et al. present SMARCB1-deficient human pluripotent stem cell-derived atypical teratoid/rhabdoid tumor (AT/RT) models and show that ESC-like signature is a critical driver of malignant phenotypes of AT/RT. Genetic ablation targeting the maintenance of pluripotency inhibits AT/RT cell growth, suggesting that the ESC-like signature could be a promising therapeutic target for AT/RT. Keywords: atypical teratoid/rhabdoid tumor, pediatric tumor, embryonic stem cell, induced pluripotent stem cell, ESC-like signature, pluripotency, dedifferentiation, SMARCB1http://www.sciencedirect.com/science/article/pii/S2211124719301718